The month of May is American Jewish History Month, so for this entire month I will share the stories of important Jewish figures in American finance. Today, I will discuss Michael Milken, who developed the market for high yield bonds and was known as the “junk bond king.”
Michael Milken was born on July 4, 1946, in Encino, California, and is an American financier known for revolutionizing the high-yield bond market, commonly referred to as "junk bonds." For those who don’t know, High-yield bonds, are debt securities issued by companies with lower credit ratings, making them more susceptible to default than investment-grade bonds. They offer higher interest rates to compensate investors for the increased risk while also providing companies that are not on strong financial footing much needed financing. Milken’s financial innovations helped provide capital to emerging businesses and fueled corporate takeovers in the 1980s.
Milken joined Drexel Burnham Lambert and by the mid-1980s, Milken’s strategies had transformed Drexel Burnham into a financial powerhouse, and he personally earned record-breaking compensation. In his highest-paid year, 1987, he earned an estimated $550 million. This figure, adjusted for inflation to 2025 dollars, would be roughly equivalent to $1.2 billion.
His influence extended beyond Wall Street, as his financing enabled entrepreneurs and corporate raiders to acquire and expand businesses. However, his aggressive tactics drew scrutiny, and in 1989, he was indicted for securities fraud and racketeering. He pleaded guilty to lesser charges, served 22 months in prison, and paid a $600 million fine. In 2020, he was pardoned by President Donald Trump.
Following his release, Milken shifted his focus to philanthropy. He founded the Milken Family Foundation and the Milken Institute, supporting medical research, education, and public health initiatives. A prostate cancer survivor, he has dedicated significant resources to cancer research.
Despite his controversial past, Milken’s financial innovations reshaped capital markets, and his philanthropic efforts have had a lasting impact on healthcare and education. His legacy remains a mix of financial ingenuity and ethical debate.